NCT06971965

Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 578 (estimated)
• Sponsor: National Cancer Center, Korea · Other Government
• Sex: All
• Age: 19 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).

Detailed description

Patients diagnosed with papillary thyroid cancer who wanted Active surveillance and meet the inclusion / exclusion criteria will be randomized 1: 1 into two groups: the high TSH and low TSH group. During the study period, thyroid hormone supplementary doses will be determined according to the dose-adjustment protocol established for each target TSH range.

Conditions

• Thyroid Cancer
• Papillary Thyroid Carcinoma

Interventions

Type	Name	Description
DRUG	Levothyroxin	During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for the group's target TSH range.

Timeline

• Start date: 2025-06-02
• Primary completion: 2027-12-31
• Completion: 2032-12-31
• First posted: 2025-05-14
• Last updated: 2025-05-14